Transplant News and Research RSS Feed - Transplant News and Research

BWH researchers identify two-faced role of TIM-3 protein

BWH researchers identify two-faced role of TIM-3 protein

A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system -- sometimes dampening it, other times stimulating it. This newly identified partner not only sheds light on the inner workings of the immune system in diseases such as HIV, autoimmunity, and cancer, but also provides a critical path toward the development of novel treatments that target TIM-3. [More]
New cell therapy offers hope for patients with liver cirrhosis

New cell therapy offers hope for patients with liver cirrhosis

Liver disease patients could be helped by a new cell therapy to treat the condition. [More]
Model G: New patient hospital gown blends style and comfort

Model G: New patient hospital gown blends style and comfort

A new Detroit design is rolling off the assembly line in the Motor City in 2015, made with a cotton-poplin blend for comfort, color-coded trim for ease of use and - most importantly - a closed backside that finally offers patients more privacy and comfort in the hospital. [More]
Excess fat in lungs may cause pulmonary fibrosis

Excess fat in lungs may cause pulmonary fibrosis

Pulmonary fibrosis has no cure. It's caused by scarring that seems to feed on itself, with the tougher, less elastic tissue replacing the ever moving and stretching lung, making it increasingly difficult for patients to breathe. [More]
Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy developed at St. Jude Children's Research Hospital, University College London and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported. [More]
Researchers find drug combination that reduces risk of skin graft rejection

Researchers find drug combination that reduces risk of skin graft rejection

A research team bringing together José Cohen and Philippe Grimbert (Inserm Unit 955/Université Paris Est Créteil [UPEC] and the Centre for Clinical Investigation - Biotherapies 504 [CIC-BT 504]), and their collaborators at Institut Curie and AP-HP (George Pompidou European Hospital) has succeeded in finding a combination of drugs that reduces the risk of rejection following a skin graft. [More]
New research suggests potential role for MEK inhibitors in type 2 diabetes

New research suggests potential role for MEK inhibitors in type 2 diabetes

A research team led by Brigham and Women's Hospital and Dana-Farber Cancer Institute has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes. [More]
Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Beckman Coulter Life Sciences is participating in the ONE Study, an international collaboration of scientists across Europe and the USA − and holding its annual general meeting in Regensburg, Germany from 19-21 November 2014. Beckman Coulter is contributing its flow cytometry expertise in cell therapy and diagnostic technologies to support the study’s specific translational research into organ transplantation and immune deficiency diseases such as HIV. [More]
Solgar voluntarily recalls ABC Dophilus Powder

Solgar voluntarily recalls ABC Dophilus Powder

Solgar, Inc., of Leonia, NJ, is voluntarily recalling ABC Dophilus Powder. The recall was initiated, out of an abundance of caution, because the product was found to contain Rhizopus oryzae, which may cause Mucormycosis. [More]
Biosafe gears up its activities in China with major expansion of Shanghai-based operations

Biosafe gears up its activities in China with major expansion of Shanghai-based operations

Following the full registration of its product range by the Chinese FDA last April, Biosafe is gearing up its activities in the People's Republic of China with a major expansion of its Shanghai-based operations, including staffing and facilities consolidation. [More]
Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

For patients with aggressive types of leukemia and other blood cancers, quickly identifying and starting the right treatment can make all the difference. [More]
New treatment regimen for hepatitis C in transplant patients produces promising results

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine. [More]
Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

One of the leading causes of blindness worldwide could be detected by how our eyes respond to watching TV according to a new study from researchers at City University London. [More]
Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection. [More]
Peter Munk Cardiac Centre surgeons successfully implant novel heart device

Peter Munk Cardiac Centre surgeons successfully implant novel heart device

A surgical team at the Peter Munk Cardiac Centre led by internationally-acclaimed cardiovascular surgeon, Dr. Vivek Rao, has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure. [More]
Researchers develop standardized, team-based approach to reduce alarm fatigue in hospitals

Researchers develop standardized, team-based approach to reduce alarm fatigue in hospitals

The sound of monitor alarms in hospitals can save patients' lives, but the frequency with which the monitors go off can also lead to "alarm fatigue," in which caregivers become desensitized to the ubiquitous beeping. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
D-LIVER project aims to help patients with chronic liver disease

D-LIVER project aims to help patients with chronic liver disease

A European ICT for Health project aims to improve the quality of life of patients with chronic liver disease, by developing a remote support system to monitor their condition at home. [More]
Common drug could become the future standard of care for HE patients

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients. [More]
VCU Massey Cancer Center researchers develop tool for measuring cancer health literacy

VCU Massey Cancer Center researchers develop tool for measuring cancer health literacy

Virginia Commonwealth University (VCU) Massey Cancer Center researchers have developed the first and only tool that can accurately measure cancer health literacy (CHL) and quickly identify patients with limited CHL. This tool has the potential to improve communication and understanding between physicians and patients, which, in turn, could lead to better clinical outcomes. [More]